中国医药
中國醫藥
중국의약
CHINA MEDICINE
2012年
11期
1418-1420
,共3页
仝用%冀玲琴%李艳颖%姚琼%杨西强%曹阿丹
仝用%冀玲琴%李豔穎%姚瓊%楊西彊%曹阿丹
동용%기령금%리염영%요경%양서강%조아단
糖尿病肾病%氧化应激%雷公藤多苷
糖尿病腎病%氧化應激%雷公籐多苷
당뇨병신병%양화응격%뢰공등다감
Diabetic nephropathies%Oxidative stress%Triptolide
目的 观察雷公藤多苷治疗糖尿病肾病(DN)Ⅲ期的疗效.方法 75例2型糖尿病并DNⅢ期患者,完全随机分为观察组(40例)和对照组(35例).观察组予以雷公藤多苷60 mg/d及氯沙坦100 mg/d,对照组给予氯沙坦100 mg/d,总疗程12周.治疗前后进行24h尿微量白蛋白(24 h Alb)、层黏连蛋白(LN)、Ⅳ型胶原(C-Ⅳ)、血浆高敏C反应蛋白(hs-CRP)的定量测定及尿中足细胞计数.结果 治疗后2组24 h Alb、尿中足细胞计数、LN、C-Ⅳ、hs-CRP均明显下降[对照组:(117±30) mg比(173±35) mg,(1.2±0.6)个/ml比(1.7±0.8)个/ml,(127±25) μg比(144±26) μg,(248±25)μg比(274±27) μg,(4.3±1.4) mg/L比(5.0±1.7) mg/L；观察组:(104±20)mg比(169±27) mg,(1.1±0.4)个/ml比(1.8±0.7)个/ml,(125±27)μg比(145±28) μg,(253±74) μg比(282±74) μg,(3.8±1.2) mg/L比(4.9±1.7)mg/L,均P＜0.05],且观察组下降更明显,其中24 h Alb、尿足细胞计数及C-Ⅳ减少差异具有统计学意义(均P＜0.05)；2组均无严重不良反应发生.结论 雷公藤多苷可以减少DNⅢ期患者尿微量白蛋白及足细胞的凋亡,炎症因子在DN的发生发展中起重要的作用.
目的 觀察雷公籐多苷治療糖尿病腎病(DN)Ⅲ期的療效.方法 75例2型糖尿病併DNⅢ期患者,完全隨機分為觀察組(40例)和對照組(35例).觀察組予以雷公籐多苷60 mg/d及氯沙坦100 mg/d,對照組給予氯沙坦100 mg/d,總療程12週.治療前後進行24h尿微量白蛋白(24 h Alb)、層黏連蛋白(LN)、Ⅳ型膠原(C-Ⅳ)、血漿高敏C反應蛋白(hs-CRP)的定量測定及尿中足細胞計數.結果 治療後2組24 h Alb、尿中足細胞計數、LN、C-Ⅳ、hs-CRP均明顯下降[對照組:(117±30) mg比(173±35) mg,(1.2±0.6)箇/ml比(1.7±0.8)箇/ml,(127±25) μg比(144±26) μg,(248±25)μg比(274±27) μg,(4.3±1.4) mg/L比(5.0±1.7) mg/L；觀察組:(104±20)mg比(169±27) mg,(1.1±0.4)箇/ml比(1.8±0.7)箇/ml,(125±27)μg比(145±28) μg,(253±74) μg比(282±74) μg,(3.8±1.2) mg/L比(4.9±1.7)mg/L,均P＜0.05],且觀察組下降更明顯,其中24 h Alb、尿足細胞計數及C-Ⅳ減少差異具有統計學意義(均P＜0.05)；2組均無嚴重不良反應髮生.結論 雷公籐多苷可以減少DNⅢ期患者尿微量白蛋白及足細胞的凋亡,炎癥因子在DN的髮生髮展中起重要的作用.
목적 관찰뢰공등다감치료당뇨병신병(DN)Ⅲ기적료효.방법 75례2형당뇨병병DNⅢ기환자,완전수궤분위관찰조(40례)화대조조(35례).관찰조여이뢰공등다감60 mg/d급록사탄100 mg/d,대조조급여록사탄100 mg/d,총료정12주.치료전후진행24h뇨미량백단백(24 h Alb)、층점련단백(LN)、Ⅳ형효원(C-Ⅳ)、혈장고민C반응단백(hs-CRP)적정량측정급뇨중족세포계수.결과 치료후2조24 h Alb、뇨중족세포계수、LN、C-Ⅳ、hs-CRP균명현하강[대조조:(117±30) mg비(173±35) mg,(1.2±0.6)개/ml비(1.7±0.8)개/ml,(127±25) μg비(144±26) μg,(248±25)μg비(274±27) μg,(4.3±1.4) mg/L비(5.0±1.7) mg/L；관찰조:(104±20)mg비(169±27) mg,(1.1±0.4)개/ml비(1.8±0.7)개/ml,(125±27)μg비(145±28) μg,(253±74) μg비(282±74) μg,(3.8±1.2) mg/L비(4.9±1.7)mg/L,균P＜0.05],차관찰조하강경명현,기중24 h Alb、뇨족세포계수급C-Ⅳ감소차이구유통계학의의(균P＜0.05)；2조균무엄중불량반응발생.결론 뢰공등다감가이감소DNⅢ기환자뇨미량백단백급족세포적조망,염증인자재DN적발생발전중기중요적작용.
Objective To investigate the effects of triptolide on diabetic nephropathy (DN).Methods Seventy-five patients of type 2 diabetes with DN of Ⅲ stage were randomized into two groups.Fourty patients in treatment group received triptolide 60 mg/d and losartan 100 mg/d,while the other 35 patients in control group received losartan 100 mg/d; with a course of 12 weeks in each group.The levels of 24 h urine albumin,laminin (LN),ⅣV-collagen(C-Ⅳ),high sensitive C-creative protein (hsCRP) and urinary podocytes were measured before and after the treatments.Results After 12 weeks of treatment,the levels of 24h urine albumin,LN,C-Ⅳ,hsCRP,and urinary podocytes in two groups decreased significantly (P ＜ 0.05) ; the level of LN and hsCRP in treatment group decreased more than that in control group(P ＞0.05) ; the level of 24 h urine albumin,C-Ⅳ and urinary podocytes in treatment group decreased more significantly than that in control group (P ＜ 0.05).No serious adverse reactions occurred in both groups.Conclusions Triptolide may decrease the amount of proteinuria of diabetic nephropathy and in DN developing.The mechanism appears to be related with suppressing expressions of inflammatory cytokines.
